Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncology Is Booming But Cost Outlook Is Grim, IMS Says

Executive Summary

The cost of oncology therapeutics and supportive care drugs grew 11.5% to $107bn in 2015 at constant exchange rates and is expected to reach $150bn globally in 2020, according to a new IMS report.

You may also be interested in...



Industry's Rebate Arms Race: Securing Market Access At A Cost

Rebates have become industry's go-to for securing market access for drugs in competitive therapeutic areas in the US. But as payers push back, competitive rebating is intensifying and eating into the bottom line.

Benefit vs cost: ASCO unveils cancer drug 'value' tool

The American Society of Clinical Oncology (ASCO) asked the question "What is a cancer drug's true value?" and in four very specific treatment situations the organization's Value in Cancer Care Task Force supplied an answer: It depends.

Darzalex Surpasses Stelara As J&J’s Best-Selling Drug

Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel